Banyu Pharmaceutical Co. Ltd

Other

Merck + Co., Inc.

Hoya Lens Thailand Ltd.

Masaki Ihara

Takehiro Fukami

Akio Kanatani

Kiyofumi Ishikawa

Mitsuo Yano

Takahiro Fukuroda

Toshio Nagase

Toshiaki Mase

Takashi Hayama

Kenji Niiyama

Kagari Fujita

Masaru Nishikibe

Fumihiko Ikemoto

Lihu Yang

Ying-Duo Gao

Douglas J MacNeil

Yasuyuki Ishii

Nancy R Morin

Toshihiko Shimizu

Yoshimi Tsuchiya

Masahiro Hayashi

Yoshio Sawasaki

Kenichi Tonouchi

Akinori Yamamoto

Takayoshi Okabe

Hiroshi Takehana

Akihiro Hisaka

Daisuke Ogaya

Takeshi Hayama

A polarizing lens including a polarizing polyvinyl alcohol film arranged between two pieces of a lens base material, where the polarizing polyvinyl alcohol film includes a hydrophobic region having higher hydrophobicity than other regions at least at a partial region of an outer periphery part including an edge surface thereof and the hydrophobic region is exposed at least at a part of an edge surface of the lens.

Polarizing lens, eyewear, and method for manufacturing polarizing lens

Spiro-indolines as Y5 receptor antagonists

NPY Y5 receptor antagonists

Compounds of general structural formula I such as that shown in structural formula II

The present invention relates to a neuropeptide Y receptor antagonist comprising a compound represented by the formula &lsqb;I&rsqb;:

Neuropeptide Y receptor antagonist

Compounds of the general structural formula I

The present invention relates to a compound represented by the general formula &lsqb;I&rsqb;:

Aminopyrazole derivatives

The present invention relates to a compound represented by the general formula [I]: ##STR1## wherein A and B rings are ortho-condensed to each other, A ring represents an aromatic carbocyclic or heterocyclic ring and B ring represents an aliphatic four- to seven-membered carbocyclic or nitrogen-containing heterocyclic ring, said nitrogen atom being possible to present at only the position where the A ring is condensed; Ar represents an aromatic carbocyclic or heterocyclic ring group which may have a substituent selected from the group consisting of a halogen atom and lower alkyl, lower alkenyl, lower haloalkyl, lower alkoxy, lower alkylthio, lower alkylamino, lower dialkylamino and aromatic carbocyclic ring groups; and R represents a substituent selected from the group consisting of a halogen atom and nitro, lower alkyl, lower alkoxy, aromatic carbocyclic ring groups and a carbonyl group having an aromatic carbocyclic ring group, or a hydrogen atom, provided that when the group represented by ##STR2## is the group represented by ##STR3## Ar is not a phenyl group nor a 4-chlorophenyl group, or its salt, a method for its preparation as well as an agent for the treatment of bulimia, obesity or diabetes comprising it as an active ingredient.

Pyrazole derivatives

Urea derivatives

Endothelin antagonistic heteroaromatic ring-fused cyclopentene

The invention relates to compounds which are antagonists of endothelin, to processes for their preparation, and to their use as pharmaceuticals. The compounds of the invention are Useful in the treatment of hypertension, pulmonary hypertension, Reynaud's disease, myocardial infarction, angina pectoris, acute renal failure, cerebral infarction, cerebral vasospasm, arteriosclerosis, asthma, endotoxin shock, endotoxin-induced multiple organ failure or disseminated intravascular coagulation, and/or cyclosporin-induced renal failure or hypertension.

Endothelin antagonistic peptide derivatives

Peptides having the formula: ##STR1## inhibit the binding of endothelin to its ET.sub.B receptor and are useful in treating diseases associated with excess production or secretion of endothelin.

Endothelin antagonistic substance

Peptides having the formula: ##STR1## inhibit the binding of endothelin and are useful in treating diseases associated with excess production or secretion of endothelin.

A peptide derivative of the formula: ##STR1## is a novel compound having antagonism against three endothelin isopeptides. A 2-cyanotryptophan or a protected compound thereof, is an intermediate for the preparation of the endothelin antagonist.

Endothelin antagonistic peptide

Growing community of inventors

Tsukuba, Japan

Masaki Ihara